Skip to main content
Top
Published in: Sleep and Breathing 1/2013

01-03-2013 | Original Article

Elevated serum cystatin C in severe OSA younger men without complications

Authors: Xiao-Bin Zhang, Qi-Chang Lin, Chao-Sheng Deng, Gong-Ping Chen, Zhi-Ming Cai, Hua Chen

Published in: Sleep and Breathing | Issue 1/2013

Login to get access

Abstracts

Purpose

Serum cystatin C is a promising new biomarker of glomerular filtration rate and cardiovascular events, but few studies focused on serum cystatin C levels in obstructive sleep apnea (OSA) patients. The aim of our study was to evaluate the association between serum cystatin C and OSA in younger men (≤40 years old of age) without complications.

Methods

We prospectively recruited consecutive participants without comorbidities who underwent polysomnography. Fasting blood samples were obtained from all subjects for biological profile measurements. Statistical analysis was used to evaluate the relationship between serum cystatin C and other parameters.

Results

The population consisted of 98 subjects (mean age = 32.5 years, mean body mass index = 27.93 kg/m2) that were divided according to polysomnographic finding into control group (n = 23), mild (n = 15), moderate (n = 24), and severe (n = 36) OSA group. Compared with the control group, patients with severe OSA were significantly heavier (body mass index, 29.69 ± 3.81 vs. 26.42 ± 3.10) and presented significantly higher levels of high sensitive C-reactive protein (hsCRP) (1.10 ± 0.28 vs. 0.88 ± 0.20 mg/l) and serum cystatin C (0.87 ± 0.12 vs. 0.74 ± 0.10 mg/l) (p < 0.05 for all comparisons). Cystatin C was correlated with Apnea Hypopnea Index (AHI), Oxygen Desaturation Index, hsCRP, creatinine, and estimated glomerular filtration rate (r = 0.319, 0.279, 0.321, 0.233, −0.241, p = 0.001, 0.005, 0.001, 0.021, 0.017, respectively). After adjustment for confounding factors, AHI was significantly and positively associated with serum cystatin C levels (β = 0.284, p = 0.007).

Conclusions

Our finding indicated that serum cystatin C was associated with the severity of OSA in younger men. Further study is needed to find out whether OSA patients with increased serum cystatin C levels are prone to subclinical cardiovascular and renal diseases.
Literature
1.
go back to reference Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S (1993) The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 328:1230–1235PubMedCrossRef Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S (1993) The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 328:1230–1235PubMedCrossRef
2.
go back to reference Deegan PC, McNicholas WT (1995) Pathophysiology of obstructive sleep apnoea. Eur Respir J 8:1161–1178PubMedCrossRef Deegan PC, McNicholas WT (1995) Pathophysiology of obstructive sleep apnoea. Eur Respir J 8:1161–1178PubMedCrossRef
3.
go back to reference Young T, Peppard P (2000) Sleep-disordered breathing and cardiovascular disease: epidemiologic evidence for a relationship. Sleep 23(Suppl 4):S122–S126PubMed Young T, Peppard P (2000) Sleep-disordered breathing and cardiovascular disease: epidemiologic evidence for a relationship. Sleep 23(Suppl 4):S122–S126PubMed
4.
go back to reference Punjabi NM, Newman AB, Young TB, Resnick HE, Sanders MH (2008) Sleep-disordered breathing and cardiovascular disease: an outcome-based definition of hypopneas. Am J Respir Crit Care Med 177:1150–1155PubMedCrossRef Punjabi NM, Newman AB, Young TB, Resnick HE, Sanders MH (2008) Sleep-disordered breathing and cardiovascular disease: an outcome-based definition of hypopneas. Am J Respir Crit Care Med 177:1150–1155PubMedCrossRef
5.
go back to reference Martinez D, Klein C, Rahmeier L, da Silva RP, Fiori CZ, Cassol CM, Goncalves SC, Bos AJ (2011) Sleep apnea is a stronger predictor for coronary heart disease than traditional risk factors. Sleep Breath. doi:10.1007/s11325-011-0559-0 Martinez D, Klein C, Rahmeier L, da Silva RP, Fiori CZ, Cassol CM, Goncalves SC, Bos AJ (2011) Sleep apnea is a stronger predictor for coronary heart disease than traditional risk factors. Sleep Breath. doi:10.​1007/​s11325-011-0559-0
6.
go back to reference Iseki K, Tohyama K, Matsumoto T, Nakamura H (2008) High prevalence of chronic kidney disease among patients with sleep related breathing disorder (SRBD). Hypertens Res 31:249–255PubMedCrossRef Iseki K, Tohyama K, Matsumoto T, Nakamura H (2008) High prevalence of chronic kidney disease among patients with sleep related breathing disorder (SRBD). Hypertens Res 31:249–255PubMedCrossRef
8.
go back to reference Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296–1305PubMedCrossRef Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296–1305PubMedCrossRef
9.
go back to reference Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108:2154–2169PubMedCrossRef Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108:2154–2169PubMedCrossRef
10.
go back to reference Dharnidharka VR, Kwon C, Stevens G (2002) Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 40:221–226PubMedCrossRef Dharnidharka VR, Kwon C, Stevens G (2002) Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 40:221–226PubMedCrossRef
11.
go back to reference Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C (2005) Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 352:2049–2060PubMedCrossRef Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C (2005) Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 352:2049–2060PubMedCrossRef
12.
go back to reference Ix JH, Shlipak MG, Chertow GM, Whooley MA (2007) Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 115:173–179PubMedCrossRef Ix JH, Shlipak MG, Chertow GM, Whooley MA (2007) Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 115:173–179PubMedCrossRef
13.
go back to reference Can M, Acikgoz S, Mungan G, Bayraktaroglu T, Kocak E, Guven B, Demirtas S (2006) Serum cardiovascular risk factors in obstructive sleep apnea. Chest 129:233–237PubMedCrossRef Can M, Acikgoz S, Mungan G, Bayraktaroglu T, Kocak E, Guven B, Demirtas S (2006) Serum cardiovascular risk factors in obstructive sleep apnea. Chest 129:233–237PubMedCrossRef
14.
go back to reference Shamsuzzaman AS, Winnicki M, Lanfranchi P, Wolk R, Kara T, Accurso V, Somers VK (2002) Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 105:2462–2464PubMedCrossRef Shamsuzzaman AS, Winnicki M, Lanfranchi P, Wolk R, Kara T, Accurso V, Somers VK (2002) Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 105:2462–2464PubMedCrossRef
15.
go back to reference Villa MP, Ianniello F, Tocci G, Evangelisti M, Miano S, Ferrucci A, Ciavarella GM, Volpe M (2011) Early cardiac abnormalities and increased C-reactive protein levels in a cohort of children with sleep disordered breathing. Sleep Breath. doi:10.1007/s11325-010-0462-0 Villa MP, Ianniello F, Tocci G, Evangelisti M, Miano S, Ferrucci A, Ciavarella GM, Volpe M (2011) Early cardiac abnormalities and increased C-reactive protein levels in a cohort of children with sleep disordered breathing. Sleep Breath. doi:10.​1007/​s11325-010-0462-0
16.
go back to reference Lee M, Saver JL, Huang WH, Chow J, Chang KH, Ovbiagele B (2010) Impact of elevated cystatin C level on cardiovascular disease risk in predominantly high cardiovascular risk populations: a meta-analysis. Circ Cardiovasc Qual Outcomes 3:675–683PubMedCrossRef Lee M, Saver JL, Huang WH, Chow J, Chang KH, Ovbiagele B (2010) Impact of elevated cystatin C level on cardiovascular disease risk in predominantly high cardiovascular risk populations: a meta-analysis. Circ Cardiovasc Qual Outcomes 3:675–683PubMedCrossRef
17.
go back to reference Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in Renal Disease Study Group. Ann Intern Med 130:461–470PubMed Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in Renal Disease Study Group. Ann Intern Med 130:461–470PubMed
18.
go back to reference Schulz H (2007) Phasic or transient? Comment on the terminology of the AASM manual for the scoring of sleep and associated events. J Clin Sleep Med 3:752PubMed Schulz H (2007) Phasic or transient? Comment on the terminology of the AASM manual for the scoring of sleep and associated events. J Clin Sleep Med 3:752PubMed
19.
go back to reference Grubb A, Nyman U, Bjork J, Lindstrom V, Rippe B, Sterner G, Christensson A (2005) Simple cystatin C-based prediction equations for glomerular filtration rate compared with the modification of diet in renal disease prediction equation for adults and the Schwartz and the Counahan-Barratt prediction equations for children. Clin Chem 51:1420–1431PubMedCrossRef Grubb A, Nyman U, Bjork J, Lindstrom V, Rippe B, Sterner G, Christensson A (2005) Simple cystatin C-based prediction equations for glomerular filtration rate compared with the modification of diet in renal disease prediction equation for adults and the Schwartz and the Counahan-Barratt prediction equations for children. Clin Chem 51:1420–1431PubMedCrossRef
20.
go back to reference Laterza OF, Price CP, Scott MG (2002) Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 48:699–707PubMed Laterza OF, Price CP, Scott MG (2002) Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 48:699–707PubMed
21.
go back to reference Pucci L, Triscornia S, Lucchesi D, Fotino C, Pellegrini G, Pardini E, Miccoli R, Del Prato S, Penno G (2007) Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients. Clin Chem 53:480–488PubMedCrossRef Pucci L, Triscornia S, Lucchesi D, Fotino C, Pellegrini G, Pardini E, Miccoli R, Del Prato S, Penno G (2007) Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients. Clin Chem 53:480–488PubMedCrossRef
22.
go back to reference Watanabe S, Okura T, Liu J, Miyoshi K, Fukuoka T, Hiwada K, Higaki J (2003) Serum cystatin C level is a marker of end-organ damage in patients with essential hypertension. Hypertens Res 26:895–899PubMedCrossRef Watanabe S, Okura T, Liu J, Miyoshi K, Fukuoka T, Hiwada K, Higaki J (2003) Serum cystatin C level is a marker of end-organ damage in patients with essential hypertension. Hypertens Res 26:895–899PubMedCrossRef
23.
go back to reference Donahue RP, Stranges S, Rejman K, Rafalson LB, Dmochowski J, Trevisan M (2007) Elevated cystatin C concentration and progression to pre-diabetes: the Western New York Study. Diabetes Care 30:1724–1729PubMedCrossRef Donahue RP, Stranges S, Rejman K, Rafalson LB, Dmochowski J, Trevisan M (2007) Elevated cystatin C concentration and progression to pre-diabetes: the Western New York Study. Diabetes Care 30:1724–1729PubMedCrossRef
24.
go back to reference Kestenbaum B, Rudser KD, de Boer IH, Peralta CA, Fried LF, Shlipak MG, Palmas W, Stehman-Breen C, Siscovick DS (2008) Differences in kidney function and incident hypertension: the multi-ethnic study of atherosclerosis. Ann Intern Med 148:501–508PubMed Kestenbaum B, Rudser KD, de Boer IH, Peralta CA, Fried LF, Shlipak MG, Palmas W, Stehman-Breen C, Siscovick DS (2008) Differences in kidney function and incident hypertension: the multi-ethnic study of atherosclerosis. Ann Intern Med 148:501–508PubMed
25.
go back to reference Parikh NI, Hwang SJ, Yang Q, Larson MG, Guo CY, Robins SJ, Sutherland P, Benjamin EJ, Levy D, Fox CS (2008) Clinical correlates and heritability of cystatin C (from the Framingham Offspring Study). Am J Cardiol 102:1194–1198PubMedCrossRef Parikh NI, Hwang SJ, Yang Q, Larson MG, Guo CY, Robins SJ, Sutherland P, Benjamin EJ, Levy D, Fox CS (2008) Clinical correlates and heritability of cystatin C (from the Framingham Offspring Study). Am J Cardiol 102:1194–1198PubMedCrossRef
26.
go back to reference Li Y, Chongsuvivatwong V, Geater A, Liu A (2008) Are biomarker levels a good follow-up tool for evaluating obstructive sleep apnea syndrome treatments? Respiration 76:317–323PubMedCrossRef Li Y, Chongsuvivatwong V, Geater A, Liu A (2008) Are biomarker levels a good follow-up tool for evaluating obstructive sleep apnea syndrome treatments? Respiration 76:317–323PubMedCrossRef
27.
go back to reference Steiropoulos P, Tsara V, Nena E, Fitili C, Kataropoulou M, Froudarakis M, Christaki P, Bouros D (2007) Effect of continuous positive airway pressure treatment on serum cardiovascular risk factors in patients with obstructive sleep apnea–hypopnea syndrome. Chest 132:843–851PubMedCrossRef Steiropoulos P, Tsara V, Nena E, Fitili C, Kataropoulou M, Froudarakis M, Christaki P, Bouros D (2007) Effect of continuous positive airway pressure treatment on serum cardiovascular risk factors in patients with obstructive sleep apnea–hypopnea syndrome. Chest 132:843–851PubMedCrossRef
28.
go back to reference Shlipak MG, Katz R, Cushman M, Sarnak MJ, Stehman-Breen C, Psaty BM, Siscovick D, Tracy RP, Newman A, Fried L (2005) Cystatin-C and inflammatory markers in the ambulatory elderly. Am J Med 118:1416PubMedCrossRef Shlipak MG, Katz R, Cushman M, Sarnak MJ, Stehman-Breen C, Psaty BM, Siscovick D, Tracy RP, Newman A, Fried L (2005) Cystatin-C and inflammatory markers in the ambulatory elderly. Am J Med 118:1416PubMedCrossRef
29.
go back to reference Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC, de Jong PE (2004) Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 65:1416–1421PubMedCrossRef Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC, de Jong PE (2004) Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 65:1416–1421PubMedCrossRef
30.
go back to reference Kato K, Takata Y, Usui Y, Shiina K, Asano K, Hashimura Y, Saruhara H, Nishihata Y, Tomiyama H, Yamashina A (2011) Severe obstructive sleep apnea increases cystatin C in clinically latent renal dysfunction. Respir Med 105:643–649PubMedCrossRef Kato K, Takata Y, Usui Y, Shiina K, Asano K, Hashimura Y, Saruhara H, Nishihata Y, Tomiyama H, Yamashina A (2011) Severe obstructive sleep apnea increases cystatin C in clinically latent renal dysfunction. Respir Med 105:643–649PubMedCrossRef
31.
go back to reference Sim JJ, Rasgon SA, Kujubu DA, Kumar VA, Liu IL, Shi JM, Pham TT, Derose SF (2009) Sleep apnea in early and advanced chronic kidney disease: Kaiser Permanente Southern California cohort. Chest 135:710–716PubMedCrossRef Sim JJ, Rasgon SA, Kujubu DA, Kumar VA, Liu IL, Shi JM, Pham TT, Derose SF (2009) Sleep apnea in early and advanced chronic kidney disease: Kaiser Permanente Southern California cohort. Chest 135:710–716PubMedCrossRef
32.
go back to reference Denton KM, Shweta A, Anderson WP (2002) Preglomerular and postglomerular resistance responses to different levels of sympathetic activation by hypoxia. J Am Soc Nephrol 13:27–34PubMed Denton KM, Shweta A, Anderson WP (2002) Preglomerular and postglomerular resistance responses to different levels of sympathetic activation by hypoxia. J Am Soc Nephrol 13:27–34PubMed
33.
go back to reference Faulx MD, Storfer-Isser A, Kirchner HL, Jenny NS, Tracy RP, Redline S (2007) Obstructive sleep apnea is associated with increased urinary albumin excretion. Sleep 30:923–929PubMed Faulx MD, Storfer-Isser A, Kirchner HL, Jenny NS, Tracy RP, Redline S (2007) Obstructive sleep apnea is associated with increased urinary albumin excretion. Sleep 30:923–929PubMed
34.
go back to reference Garg AX, Kiberd BA, Clark WF, Haynes RB, Clase CM (2002) Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. Kidney Int 61:2165–2175PubMedCrossRef Garg AX, Kiberd BA, Clark WF, Haynes RB, Clase CM (2002) Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. Kidney Int 61:2165–2175PubMedCrossRef
35.
go back to reference Schuck O, Teplan V, Stollova M, Skibova J (2004) Estimation of glomerular filtration rate in obese patients with chronic renal impairment based on serum cystatin C levels. Clin Nephrol 62:92–96PubMed Schuck O, Teplan V, Stollova M, Skibova J (2004) Estimation of glomerular filtration rate in obese patients with chronic renal impairment based on serum cystatin C levels. Clin Nephrol 62:92–96PubMed
Metadata
Title
Elevated serum cystatin C in severe OSA younger men without complications
Authors
Xiao-Bin Zhang
Qi-Chang Lin
Chao-Sheng Deng
Gong-Ping Chen
Zhi-Ming Cai
Hua Chen
Publication date
01-03-2013
Publisher
Springer-Verlag
Published in
Sleep and Breathing / Issue 1/2013
Print ISSN: 1520-9512
Electronic ISSN: 1522-1709
DOI
https://doi.org/10.1007/s11325-012-0678-2

Other articles of this Issue 1/2013

Sleep and Breathing 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.